AIMS/HYPOTHESIS: It has been suggested that uncoupling protein 3 (UCP3) can increase energy expenditure, thereby regulating body weight. Although studies on UCP3 knock-out mice suggest that lack of UCP3 function does not cause obesity or Type 2 diabetes, it is possible that up-regulation of UCP3 function improves these disorders or their clinical sequelae. A 10- to 20-fold increase of UCP3 gene expression is achievable through physiological or pharmacological stimuli. We examined the phenotype of transgenic mice with approximately 18-fold overexpression of mouse UCP3 mRNA in skeletal muscle. METHODS: We generated transgenic mice with approximately 18-fold overexpression of mouse UCP3 mRNA in skeletal muscle under control of the skeletal muscle-specific muscle creatine kinase gene promoter. The phenotype of these mice was analysed either on a standard diet or on a 4-week high-fat diet. RESULTS: In mice on standard chow, there was no difference in body weight, oxygen consumption and mitochondrial protonmotive force between transgenic mice and non-transgenic littermates. However, transgenic mice tended to have lower body weight, increased oxygen consumption and decreased mitochondrial protonmotive force than the control mice. Transgenic mice on a 4-week high-fat diet consumed much more oxygen and had noticeably less weight gain and less epididymal fat, as well as better glucose tolerance than non-transgenic littermates. CONCLUSIONS/ INTERPRETATION: Our study shows that 18-fold overexpression of UCP3 mRNA in the skeletal muscle reduced diet-induced obesity. An 18-fold increase of UCP3 mRNA can be attained by physiological or pharmacological stimuli, suggesting that UCP3 has therapeutic potential in the treatment of obesity.
AIMS/HYPOTHESIS: It has been suggested that uncoupling protein 3 (UCP3) can increase energy expenditure, thereby regulating body weight. Although studies on UCP3 knock-out mice suggest that lack of UCP3 function does not cause obesity or Type 2 diabetes, it is possible that up-regulation of UCP3 function improves these disorders or their clinical sequelae. A 10- to 20-fold increase of UCP3 gene expression is achievable through physiological or pharmacological stimuli. We examined the phenotype of transgenic mice with approximately 18-fold overexpression of mouseUCP3 mRNA in skeletal muscle. METHODS: We generated transgenic mice with approximately 18-fold overexpression of mouseUCP3 mRNA in skeletal muscle under control of the skeletal muscle-specific muscle creatine kinase gene promoter. The phenotype of these mice was analysed either on a standard diet or on a 4-week high-fat diet. RESULTS: In mice on standard chow, there was no difference in body weight, oxygen consumption and mitochondrial protonmotive force between transgenic mice and non-transgenic littermates. However, transgenic mice tended to have lower body weight, increased oxygen consumption and decreased mitochondrial protonmotive force than the control mice. Transgenic mice on a 4-week high-fat diet consumed much more oxygen and had noticeably less weight gain and less epididymal fat, as well as better glucose tolerance than non-transgenic littermates. CONCLUSIONS/ INTERPRETATION: Our study shows that 18-fold overexpression of UCP3 mRNA in the skeletal muscle reduced diet-induced obesity. An 18-fold increase of UCP3 mRNA can be attained by physiological or pharmacological stimuli, suggesting that UCP3 has therapeutic potential in the treatment of obesity.
Authors: J C Clapham; J R Arch; H Chapman; A Haynes; C Lister; G B Moore; V Piercy; S A Carter; I Lehner; S A Smith; L J Beeley; R J Godden; N Herrity; M Skehel; K K Changani; P D Hockings; D G Reid; S M Squires; J Hatcher; B Trail; J Latcham; S Rastan; A J Harper; S Cadenas; J A Buckingham; M D Brand; A Abuin Journal: Nature Date: 2000-07-27 Impact factor: 49.962
Authors: C Son; K Hosoda; J Matsuda; J Fujikura; S Yonemitsu; H Iwakura; H Masuzaki; Y Ogawa; T Hayashi; H Itoh; H Nishimura; G Inoue; Y Yoshimasa; Y Yamori; K Nakao Journal: Endocrinology Date: 2001-10 Impact factor: 4.736
Authors: J Matsuda; K Hosoda; H Itoh; C Son; K Doi; T Tanaka; Y Fukunaga; G Inoue; H Nishimura; Y Yoshimasa; Y Yamori; K Nakao Journal: FEBS Lett Date: 1997-11-24 Impact factor: 4.124
Authors: Y Ogawa; H Masuzaki; K Hosoda; M Aizawa-Abe; J Suga; M Suda; K Ebihara; H Iwai; N Matsuoka; N Satoh; H Odaka; H Kasuga; Y Fujisawa; G Inoue; H Nishimura; Y Yoshimasa; K Nakao Journal: Diabetes Date: 1999-09 Impact factor: 9.461
Authors: Y Yamamoto; Y Yoshimasa; M Koh; J Suga; H Masuzaki; Y Ogawa; K Hosoda; H Nishimura; Y Watanabe; G Inoue; K Nakao Journal: Diabetes Date: 2000-03 Impact factor: 9.461
Authors: J Matsuda; K Hosoda; H Itoh; C Son; K Doi; I Hanaoka; G Inoue; H Nishimura; Y Yoshimasa; Y Yamori; H Odaka; K Nakao Journal: Diabetes Date: 1998-11 Impact factor: 9.461
Authors: S Larkin; E Mull; W Miao; R Pittner; K Albrandt; C Moore; A Young; M Denaro; K Beaumont Journal: Biochem Biophys Res Commun Date: 1997-11-07 Impact factor: 3.575
Authors: C Tiraby; G Tavernier; F Capel; A Mairal; F Crampes; J Rami; C Pujol; J A Boutin; D Langin Journal: Diabetologia Date: 2007-08-04 Impact factor: 10.122
Authors: Leonardo Nogara; Nariman Naber; Edward Pate; Marcella Canton; Carlo Reggiani; Roger Cooke Journal: Proc Natl Acad Sci U S A Date: 2016-10-31 Impact factor: 11.205
Authors: Danny K Asami; Roger B McDonald; Kevork Hagopian; Barbara A Horwitz; David Warman; Aileen Hsiao; Craig Warden; Jon J Ramsey Journal: Exp Gerontol Date: 2008-09-30 Impact factor: 4.032
Authors: Harini Sampath; Matthew T Flowers; Xueqing Liu; Chad M Paton; Ruth Sullivan; Kiki Chu; Minghui Zhao; James M Ntambi Journal: J Biol Chem Date: 2009-05-08 Impact factor: 5.157
Authors: Eric Bombardier; Ian C Smith; Daniel Gamu; Val A Fajardo; Chris Vigna; Ryan A Sayer; Subash C Gupta; Naresh C Bal; Muthu Periasamy; A Russell Tupling Journal: FASEB J Date: 2013-06-10 Impact factor: 5.191